Building on the understanding of how prostaglandins and leukotrienes contribute to inflammation and pain, glucocorticoids like hydrocortisone and dexamethasone offer another layer of therapeutic action. These compounds, which belong to the corticosteroid family, work by intervening at the cellular level to block the conversion of phospholipids to arachidonic acid. This step is critical because it effectively reduces the production of not only prostaglandins but also leukotrienes—another group of inflammatory mediators not targeted by NSAIDs.
Glucocorticoids exert their effects deep within the cell nucleus, where they alter the cell’s genetic activity. Specifically, they decrease the transcription of genes that promote inflammation while increasing the transcription of genes that suppress inflammatory responses. This dual action helps to dampen the overall inflammatory process, leading to a reduction in inflammatory pain.
Additionally, glucocorticoids have been shown to decrease the spontaneous firing of action potentials in injured nerves, which occurs both in the central and peripheral nervous systems. This reduction in nerve excitability further contributes to their pain-relieving properties, making glucocorticoids a powerful option for controlling severe inflammation and associated pain.
